Možnosti dlouhodobé antiagregační léčby na počátku 21. století
| Title in English | Possibilities of long-term antiaggregation therapy on the threshold of a new century |
|---|---|
| Authors | |
| Year of publication | 2006 |
| Type | Article in Periodical |
| Magazine / Source | Kardiofórum |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | primary and secondary prevention – antithrombotics |
| Description | Possibilities of long-term antiaggregation therapy on the threshold of a new century. Antiaggregation therapy is one of the basic therapeutic measures of secondary prevention in treatment of atherosclerosis complications. As such, it should be a follow-up to all the other therapeutic measures. The aim of further research is to make this therapy more effective and to reduce its side effects. Acetylsalicylic acid remains the basic antiplatelet agent that can reduce serious vascular accidents in patients with symptomatic atherosclerosis by 25%. Antagonists of ADP receptors (clopidogrel and ticopidine) are more efficient than ASA, as they reduce the risk of vascular accidents by another 10% (yet they increase therapy costs). Combination of acetylsalicylic acid with antagonists of ADP receptor is significantly more efficient in preventing thrombotic complications than individual antiplatelet drugs alone; this therapy is indispensable in intervention surgeries and after acute coronary syndromes. Until now we cannot use this combination in treatment of acute cerebral vascular accidents because of extensive haemorrhage. However, the combination is less efficient in prevention of embolization during atrial fibrillation as compared with anticoagulation therapy. Today we wait for the results of studies of combination antiplatelet therapy in secondary prevention of atherosclerosis. At the same time, intensive research of new substances combining antiplatelet and anticoagulation properties is in progress. |
| Related projects: |